VOYAGE phase 3: Dupilumab significantly reduced asthma exacerbations in children age 6-11

Results from the VOYAGE study of dupilumab (Dupixent) showed that the monoclonal antibody significantly reduced exacerbations in children ages 6-11 with uncontrolled moderate-to-severe asthma, compared to placebo, according to research presented at the ATS 2021 International Conference. VOYAGE (NCT02948959) is a recently completed randomized, placebo-controlled double-blind multicenter phase 3 clinical trial, that took place in a number of countries.

Share:

Facebook
Twitter
Pinterest
LinkedIn

Leave a Reply

Related Posts

Vitamins and Minerals

Vitamins and minerals are micronutrients required by the body to carry out a range of normal functions. However, these micronutrients are not produced in our